Stryker (SYK) Q3 2026 Earnings Call Transcript

Stryker (SYK) reported Q3 2026 earnings, with organic sales growth of 7.7% and adjusted EPS of $3.52. The company faced delays in new product sales due to a cyber incident and SAP implementation but remains confident in long-term growth. Stryker updated its guidance, expecting similar Q4 growth. Recent acquisitions include ZuriMED and an investment in CMR Surgical. Vascular business showed sequential improvement, and the company anticipates commercializing AVS' IVL platform in 2027.

Original reporting
Published Oct 30, 2026, 2:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stryker (SYK) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$SYKBearishMed
01

Why it matters

The call provides decision-relevant updates: updated organic growth expectations for Q4, full-year effective tax rate guidance, and a supply normalization path for Peripheral Vascular, alongside M&A and strategic investment announcements.

02

Market read

Traders can update near-term expectations for Stryker’s Q4 organic growth and EPS trajectory based on margin expansion and supply normalization, while monitoring execution risks in new product sales.

03

What to watch

Vascular outlook depends on continued normalization of inventory and availability through year-end, plus timing of AVS IVL platform commercialization and PEERLESS II FlowTriever data in 2027.

Relevance 8/10Novelty 6/10Timing: during/after the Q3 earnings call, ahead of Q4 positioning

Background

This is a Q3 2026 earnings call transcript for Stryker, covering segment performance, margin drivers, supply disruption in Vascular, and updates on new product commercialization and pipeline data.

Company-level read

Ticker impact

$SYKBearishMedium confidence
Context

Stryker reports Q3 results and updated full-year outlook, including organic sales growth, EPS, margin expansion, and supply normalization guidance.

Expected impact

Likely modest upward bias as investors weigh margin expansion and normalized inventory expectations against commercial execution delays.

Evidence & confidence

The transcript includes specific Q3 performance metrics (organic sales, adjusted EPS, margins) plus an updated outlook and supply normalization through year-end, which are direct inputs to near-term valuation.

Market effects

Signals continued demand strength across MedSurg, Endoscopy, and Instruments, with ongoing execution risk around new product commercialization.

Highlights geographic growth leadership in Australia, Germany, Canada, and India, relevant for regional medtech demand expectations.

Reinforces broad-based procedure environment assumptions and elevated capital demand for surgical systems and enabling technologies.

Counterpoint

Despite margin expansion, the company is behind expectations on new product sales (Mako RPS and Triathlon Gold) and cites cyber incident and SAP implementation as execution headwinds.

Key entities

  • Stryker

    Reports Q3 2026 results, updated outlook, and discusses supply normalization, margin expansion, and new product execution issues.

  • ZuriMED

    Stryker completed acquisition to expand support in sports medicine and arthroplasty, including fiber locker technology.

  • CMR Surgical

    Stryker announced a strategic investment and an exclusive U.S. sales agency agreement for the Versius platform.

Related articles

Low

Bulgaria accepts first five US M1126 Stryker ICV armored vehicles under $1.4 billion Army modernization.

Bulgaria has received the first five of 183 Stryker armored vehicles under a $1.4 billion modernization deal. The order includes various configurations, with deliveries delayed due to component shortages. General Dynamics Land Systems-Canada manufactures the vehicles, and TEREM-Ivaylo handles final assembly and testing. The project's cost has increased by 2.76% due to inflation and other factors.

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.